Objectives: To compare the effects of hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis.
Methods: A six month randomised, multicentre, double blind trial with three parallel groups was performed. Ninety one outpatients with active rheumatoid arthritis were included. Monthly assessments of erythrocyte sedimentation rate, morning stiffness, number of swollen joints, a pain score, and global assessments were carried out. Radiographs of hands and wrists were taken before and after the trial.
Results: Sixty two patients completed the study. The 29 withdrawals caused no evident bias, and there was no difference in side effects among the three groups. All variables improved significantly with time. Patients treated with a combination of hydroxychloroquine and sulphasalazine responded better and faster than those treated with hydroxychloroquine alone, but there was no statistically significant difference between the combination treatment and single drug treatment with sulphasalazine or between treatment with hydroxychloroquine and sulphasalazine given alone.
Conclusion: The present results do not support a recommendation to use a combination of hydroxychloroquine and sulphasalazine in the treatment of rheumatoid arthritis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1005166 | PMC |
| http://dx.doi.org/10.1136/ard.52.10.711 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Rare Case of Fatal Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome in a Patient with Rheumatoid Arthritis.
Curr Drug Saf
January 2025
Topiwala National Medical College & BYL Nair Charitable Hospital, Clinical Pharmacology, India.
Introduction: This case study presents a rare and fatal instance of Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome in a 51-year-old male patient diagnosed with Rheumatoid Arthritis (RA).
Case Presentation: The patient was initially treated with sulfasalazine, leflunomide, and hydroxychloroquine, following which he developed a rash, fever, and loose stools. Drug allergy was suspected, and the antirheumatic medications were withdrawn, following which, the patient improved.
Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study.
Rheumatology (Oxford)
December 2024
Centre for Rheumatic Diseases, Department of Inflammation Biology, King's College London, London, UK.
Objectives: To update the first-line conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) prescribing pattern, describe change and variation across demographical and geographical factors in the Rheumatoid arthritis (RA) population, and identify individual and hospital factors associated with it.
Methods: This retrospective cohort study included newly diagnosed RA adult patients from 1 May 2018-1 April 2023 in the UK. We used adjusted multinomial logistic regression with random effect to explore associations with different first-line csDMRAD prescription and to account for hospital-level clustering.
Sustained DMARD-free remission in subgroups of patients with rheumatoid arthritis: an analysis of two prospective cohorts with early arthritis.
Lancet Rheumatol
December 2024
Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands; Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands.
Background: About 20% of patients with rheumatoid arthritis on disease-modifying antirheumatic drugs (DMARDs) can reach sustained DMARD-free remission. Nonetheless, the 2022 EULAR recommendations discourage complete cessation of DMARDs due to flare risk. The evidence behind this recommendation is obtained from trial populations using biological DMARDs, representing only a subgroup of the total population of patients with rheumatoid arthritis.
View Article and Find Full Text PDF[Evidence map of chikungunya treatmentsMapa de la evidencia sobre el tratamiento del chikunguña].
Rev Panam Salud Publica
October 2024
Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde (BIREME) São Paulo (SP) Brasil Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde (BIREME), São Paulo (SP), Brasil.
Objective: Based on a review of the literature, to create a map of the available evidence on the treatment methods for chikungunya.
Method: In May 2022, a literature search on chikungunya was conducted using the PubMed and Virtual Health Library platforms. To create the evidence map, studies that mentioned chikungunya fever were selected and characterized based on the type of intervention, outcome, and direction of the effect (positive, negative, potentially positive or potentially negative, inconclusive, or no effect), following the methodology recommended by the Latin American and Caribbean Center on Health Sciences Information (BIREME).
Survey self-report of rheumatoid arthritis and treatments versus specialist clinician confirmation.
BMC Rheumatol
October 2024
Division of Occupational Environmental and Climate Medicine, University of California San Francisco, San Francisco, CA, 94143-0843, USA.
Article Synopsis
- The study aimed to compare patient surveys on arthritis conditions and medication with physician records to enhance the accuracy of epidemiological research on autoimmune arthritis.
- Rheumatologists recruited men aged 50 and older with rheumatoid arthritis, and both patients and clinicians provided data through interviews and chart abstractions, respectively.
- Results showed complete agreement on RA diagnoses and varied levels of agreement for medication usage, indicating that patient self-reports can effectively contribute to epidemiological studies on arthritis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!